CAR-T therapy patients monitored for years in new safety study
NCT ID NCT07474051
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is purely a long-term safety check.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cell therapy (UniCAR or RevCAR platforms)
- What this could lead to
- If successful, this study could provide crucial safety data to support the broader use of these CAR-T therapies.
- What could go wrong
- This is a long-term follow-up study, not a treatment trial. It cannot prove the therapy works, and results depend on patient participation and data quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité Universitätsmedizin Berlin
Berlin, Germany
-
Klinikum der Universität (LMU) Muenchen
Munich, Germany
-
Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
-
Universitatsklinikum Ulm
Ulm, Germany
-
Universitätsklinikum Marburg
Marburg, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Can specially trained immune cells flush out hidden HIV?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can precision protons spare the bowel in prostate cancer?